AstraZeneca PLC (NASDAQ: AZN) shares are trading higher after the company reported better-than-expected EPS and sales results.
AstraZeneca reported first-quarter adjusted earnings per share of $0.82, which beat analyst estimates of $0.75. The company also reported sales results of $7.32 billion, which beat analyst estimates of $7.08 billion.
AstraZeneca sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology.
AstraZeneca’s stock was trading up 4% at $53.43 at the time of publication. The stock has a 52-week high of $64.94 and a 52-week low of $46.48.
(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
